Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis.
about
CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for NeuroprotectionMicroglial cell dysregulation in brain aging and neurodegenerationRedox control of microglial function: molecular mechanisms and functional significanceNT-020 treatment reduces inflammation and augments Nrf-2 and Wnt signaling in aged ratsModulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseasesChronic Oxidative Stress, Mitochondrial Dysfunction, Nrf2 Activation and Inflammation in the Hippocampus Accompany Heightened Systemic Inflammation and Oxidative Stress in an Animal Model of Gulf War IllnessNRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology.Modulating neurotoxicity through CX3CL1/CX3CR1 signaling.Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation.Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?Alterations of the Neuroinflammatory Markers IL-6 and TRAIL in Alzheimer's Disease.Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.Fractalkine Receptor Deficiency Is Associated with Early Protection but Late Worsening of Outcome following Brain Trauma in MiceRepurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's DiseaseTargeting microglia for the treatment of Alzheimer's disease.Fractalkine in the nervous system: neuroprotective or neurotoxic molecule?The chemokine fractalkine (CX3CL1) attenuates H2O2-induced demyelination in cerebellar slices.Transcriptional control of microglia phenotypes in health and disease.Transcription factor NRF2 controls the fate of neural stem cells in the subgranular zone of the hippocampus.KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients.Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes.Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.Tauopathies: Mechanisms and Therapeutic Strategies.Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer's disease.Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review.Association of the CX3CR1-V249I Variant with Neurofibrillary Pathology Progression in Late-Onset Alzheimer's Disease.Valproic Acid Attenuates Traumatic Brain Injury-Induced Inflammation in Vivo: Involvement of Autophagy and the Nrf2/ARE Signaling Pathway.Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy.Roles of Microglial and Monocyte Chemokines and Their Receptors in Regulating Alzheimer's Disease-Associated Amyloid-β and Tau Pathologies
P2860
Q26739374-57655DCA-A389-4370-B37F-BF950C9DDE09Q26800212-62C0B9F8-1D29-42B4-A81E-C599F6DE24A7Q27000279-E68DD7D0-EB51-4BB7-8164-10FA8D48A33BQ28388958-5EE55FA3-542F-4823-815E-15E5363518DDQ29247921-981A1737-DFCB-4BC4-84AB-AF6CA56829CBQ33794702-533E260D-505B-41F5-953F-321AE0FA78C5Q33900736-C8D83BCC-834E-4586-B3D4-182E0708F14BQ34019783-28B827EB-4972-4AE6-A000-7C71FB304F77Q34075866-B44ABF36-AA28-453C-89F5-283038C2D128Q36241505-ECA5330B-6007-4FC5-9064-7D811FC52D71Q36368183-F8A6990C-995C-4C82-A8EA-5AC31C8D274FQ36732766-AA1CBED0-53CE-47D0-A7C1-18FD58F228D9Q36966520-245C3183-DE2F-4C5C-A942-24D103A3F3BEQ37091371-120CED6C-ACFF-4E74-B204-E6F3969681D5Q38272915-3BD96ED9-096A-451B-ADF4-9E94879063F4Q38530348-18695F2A-B415-4D3D-BFC2-12BC53514869Q38623418-26B0DD40-9753-4D63-B255-64DAC8AAE025Q38649395-9CA413B6-784C-40BE-9FCB-C751B4AF703FQ38698838-AAEE2B81-6439-4E06-A331-46B60E475A67Q39375357-3D32D185-3AC7-47BA-BC46-290F099B9BBEQ41575678-063D221F-CD32-47B8-BF15-197C2F42BF4EQ41662736-D03A31AD-EFC8-4400-9DAC-20F6D89E6FCCQ47113551-98418B43-6D06-4DB2-986F-A01C48DB9801Q47253592-67FC3FD0-2B30-4446-B20A-97F378169F55Q47784892-2B61143C-8BC1-4199-84EF-89107E811090Q47920956-BA33929C-6507-4043-91E4-B9CE71543873Q48361868-1739BADF-67DF-48FE-B52E-BF2950F18B60Q55375016-0F7B6489-32A6-4EA5-A36E-37EF91DE12F5Q55715569-B3E3E2A0-F598-4986-9E50-4EF66DD5CB22Q58780923-391A8989-C522-4D85-84CE-46039E57A191
P2860
Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Fractalkine activates NRF2/NFE ...... auopathy-induced microgliosis.
@en
Fractalkine activates NRF2/NFE ...... auopathy-induced microgliosis.
@nl
type
label
Fractalkine activates NRF2/NFE ...... auopathy-induced microgliosis.
@en
Fractalkine activates NRF2/NFE ...... auopathy-induced microgliosis.
@nl
prefLabel
Fractalkine activates NRF2/NFE ...... auopathy-induced microgliosis.
@en
Fractalkine activates NRF2/NFE ...... auopathy-induced microgliosis.
@nl
P2093
P2860
P50
P356
P1433
P1476
Fractalkine activates NRF2/NFE ...... tauopathy-induced microgliosis
@en
P2093
Alberto Rábano
Fred Van Leuven
Nadia G Innamorato
P2860
P356
10.1093/BRAIN/AWT323
P407
P577
2013-11-25T00:00:00Z